OR WAIT null SECS
Oval Medical Technologies (Oval) has revealed that it is relocating to a specifically designed facility in Cambridge Research Park in the United Kingdom as a result of growth.
Patient-centric autoinjector specialist, Oval Medical Technologies (Oval), has revealed that it is relocating to a specifically designed facility in Cambridge Research Park in the United Kingdom as a result of growth.
In an Aug. 22, 2019 press release, Oval confirmed that the new facility will incorporate dedicated good manufacturing practice labs, increased capacity for the expanded team, and room for further growth, which the company predicts will result from increasing demand by pharma companies for injection platforms to deliver subcutaneous and intramuscular formulations.
“Our autoinjector platforms are creating huge opportunities for pharmaceutical companies to develop new products and to improve established formulations,” said Barbara Lead, CEO of Oval Medical Technologies, in the press release. “This move provides the needed space to continue to grow and develop cutting edge technology platforms serving pharmaceutical companies and patients.”
“Our principal aim is to partner our patient-centric autoinjectors with an integrated start to finish solution-one that’s easy for patients and easy for partners. Our expanded new facility makes that objective more achievable,” added Oval’s chief technology officer, Matthew Young, in the press release.